Can Psilocybin ease Parkinson's symptoms?

When most people think of Parkinson’s disease, they imagine the tremors, stiffness, and slowed movements that made Michael J. Fox’s diagnosis so public decades ago. But what often goes unmentioned are the invisible battles many patients fight every day, crippling depression, anxiety, and emotional distress. These mood problems make life harder but also accelerate decline, sap resilience, and rob people of the ability to cope with their illness.

Unfortunately, modern medicine hasn’t given Parkinson’s patients much relief on this front. Antidepressants often don’t work well in this group, and there have been surprisingly few clinical trials exploring alternatives. That’s why a team of researchers at the University of California, San Francisco (UCSF), the San Francisco Veterans Affairs Medical Center, the California Institute of Integral Studies, and even the Centre for Psychedelic Research at Imperial College London decided to test psilocybin therapy, better known as the active ingredient in “magic mushrooms.”

Their study, published in Neuropsychopharmacology, marks the first-ever clinical trial of psilocybin in people with any neurodegenerative disease. And the results? Promising, to say the least.

Why try psilocybin?

Psilocybin has been making headlines for its ability to lift depression and ease end-of-life anxiety in cancer patients. Unlike traditional antidepressants that must be taken daily, a single guided session with psilocybin, combined with psychotherapy, can sometimes provide relief that lasts for weeks or months. Scientists believe psilocybin acts as a “psychoplastogen,” jump-starting the brain’s ability to rewire itself, a process known as neuroplasticity.

But until now, people with conditions like Parkinson’s were excluded from such trials. Doctors worried that psilocybin might worsen psychosis (a common late-stage symptom of Parkinson’s), interact badly with medications, or stress fragile cardiovascular systems. The UCSF team, led by psychiatrist Dr. Ellen Bradley, wanted to see whether those fears were justified, or whether psilocybin might actually help.

The study was small, as it involved just 12 participants with mild to moderate Parkinson’s disease, all struggling with depression or anxiety. The average age was 63, and most had been living with the condition for about four and a half years.

Each participant underwent two carefully monitored psilocybin sessions at UCSF’s research unit. The first was a 10 mg “safety dose”, followed two weeks later by a 25 mg “therapeutic dose”. Importantly, every participant had a therapist by their side, guiding them before, during, and after the psychedelic experience. These therapy sessions were just as crucial as the drug itself, they helped patients prepare for what to expect, make sense of their experiences, and integrate new perspectives into their daily lives.

What happened?

The results came with many good news. No serious safety problems occurred. While some patients experienced nausea, anxiety, or temporary spikes in blood pressure, none required medical intervention. Crucially, there was no worsening of Parkinson’s symptoms or psychosis. But what stunned researchers were the improvements. Depression scores dropped significantly within a week of treatment and stayed better for at least three months. Anxiety also improved, particularly right after the sessions, with benefits lingering at follow-up. Surprisingly, patients didn’t just feel emotionally lighter, they also moved better. Measures of tremor, stiffness, and daily motor function all showed improvements, lasting up to a month after treatment. On memory and problem-solving tests, participants performed better after psilocybin. Their cognitive flexibility, the ability to adapt to new situations and shift thinking, also improved, which may be key to coping with a progressive illness. Family members and caregivers noticed changes too. They reported fewer distressing neuropsychiatric symptoms and said their loved ones seemed more engaged and resilient. In short, psilocybin didn’t just ease depression, it appeared to help across the board: mood, movement, and mental sharpness.

Why might this work?

The researchers outline a few possible explanations. First, psilocybin interacts with serotonin receptors that are deeply connected to both mood and motor control. It may boost dopamine circuits indirectly, which are damaged in Parkinson’s. Second, by promoting neuroplasticity, that is, the ability to form new brain connections, psilocybin might help the nervous system adapt and compensate for losses caused by the disease. Third, mood-motor connection. Depression itself can worsen physical symptoms. Lifting mood could reduce stress hormones and inflammation, indirectly easing motor problems. Finally, preclinical studies show psychedelics can reduce brain inflammation, an important contributor to Parkinson’s progression.

While no one can yet pinpoint the exact mechanism, the results hint that psilocybin’s benefits may go deeper than mood alone.

However...

Before anyone rushes to conclusions, the scientists are quick to caution. This was a pilot study. With only 12 participants and no placebo group, it’s impossible to rule out placebo effects, especially since psychedelics are known for strong expectations. Also, not all experiences were easy. Two participants had particularly difficult trips, with severe anxiety during the session. One even reported increased thoughts about medically assisted dying (though not active suicidal intent). Another factor that must be taken into account is that the population was selective. Patients with severe Parkinson’s, dementia, or major cardiovascular issues weren’t included. It’s unclear if the results would hold in those groups. Although the number of participants was too small to draw conclusive results, for a first attempt, the safety profile was reassuring and the improvements quite significant.

A new horizon for Parkinson’s care?

For decades, Parkinson’s research has focused almost exclusively on motor symptoms, how to control tremor and stiffness with medications like levodopa. But patients consistently say that non-motor symptoms, depression, anxiety, fatigue, sleep problems, can be just as debilitating, if not more so. The study also raises questions for the future of Parkinson's treatment in general. Could psilocybin actually slow aspects of Parkinson’s progression? Could boosting neuroplasticity and reducing inflammation help preserve function longer? Or is the real benefit more psychological, helping patients adapt, cope, and find meaning despite their diagnosis? Only larger, randomized trials can answer those questions. And those are exactly what researchers are now pushing for, and for the millions worldwide living with Parkinson’s, this research is a leap into hope.

If you want to learn more, the original article titled "Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial" on Neuropsychopharmacology at https://doi.org/10.1038/s41386-025-02097-0.